Linked Life Data

17712746

Source:http://linkedlifedata.com/resource/pubmed/id/17712746

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-8-22
pubmed:abstractText
Vancomycin is effective against methicillin-resistant Staphylococcus aureus and has been widely used in the past few years. However, several recent reports have highlighted the limitations of vancomycin, and its role in the management of serious infections is now being reconsidered. Vancomycin treatment failure rates are associated with an increase in the minimum inhibitory concentration as well as a decrease in the rate of bacterial killing. The intrinsic limitations of vancomycin also include poor tissue penetration, particularly in the lung; relatively slow bacterial killing; and the potential for toxicity. In addition, intermediate-level vancomycin resistance has emerged among staphylococci, as have rare cases of fully resistant strains. Because of these problems, when using vancomycin, it is probably prudent to carefully establish the diagnosis, test for antimicrobial susceptibility, and monitor serum trough concentrations to ensure adequate dosing.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1537-6591
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
45 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S191-5
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Limitations of vancomycin in the management of resistant staphylococcal infections.
pubmed:affiliation
Medical Intensive Care Unit and Respiratory Care Services, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine and Barnes-Jewish Hospital, St. Louis, MO 63110, USA. mkollef@im.wustl.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't